Edition:
United Kingdom

Cellect Biotechnology Ltd (APOP.OQ)

APOP.OQ on NASDAQ Stock Exchange Capital Market

4.08USD
15 Nov 2018
Change (% chg)

$-0.34 (-7.69%)
Prev Close
$4.42
Open
$4.42
Day's High
$4.42
Day's Low
$4.00
Volume
1,970
Avg. Vol
3,581
52-wk High
$13.50
52-wk Low
$4.00

Latest Key Developments (Source: Significant Developments)

Cellect Biotechnology reports third quarter results
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD QTRLY LOSS PER SHARE $0.014.CELLECT BIOTECHNOLOGY - CASH AND CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $6.45 MILLION AS OF SEPT 30 VERSUS $8.26 MILLION ON JUNE 30.  Full Article

Cellect Biotechnology Q1 Loss Per Ads $0.16
Thursday, 17 May 2018 

May 17 (Reuters) - Cellect Biotechnology Ltd ::CELLECT BIOTECHNOLOGY LTD PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.CELLECT BIOTECHNOLOGY LTD - QTRLY BASIC AND DILUTED LOSS PER ADS $0.16.CELLECT BIOTECHNOLOGY LTD - CASH AND CASH EQUIVALENTS, MARKETABLE SECURITIES AND SHORT-TERM DEPOSITS TOTALED $9.8 MILLION AS OF MARCH 31, 2018.  Full Article

Cellect Announces Opening Of Second Clinical Trial Site And Approval From Safety Board (DSMB) For Dose Escalation
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Cellect Biotechnology Ltd ::CELLECT ANNOUNCES OPENING OF A SECOND CLINICAL TRIAL SITE AND APPROVAL FROM SAFETY BOARD (DSMB) FOR DOSE ESCALATION.CELLECT BIOTECHNOLOGY - ‍SIGNED AGREEMENT WITH HADASSAH MEDICAL CENTER TO CONDUCT CLINICAL TRIALS ON CANCER PATIENTS IN CO'S ONGOING PHASE I/II STUDY​.CELLECT BIOTECHNOLOGY -‍ GOT APPROVAL FROM DSMB TO ESCALATE APOGRAFT FASL PROTEIN DOSAGE TO 25 NG/ML, ENROLL 3 ADDITIONAL PATIENTS FOR CLINICAL TRIAL​.  Full Article

Cellect Biotechnology reports Q3 ‍loss $0.02/shr​
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Cellect Biotechnology Ltd :Cellect Biotechnology Ltd provides corporate update and reports third quarter 2017 financial results.Cellect Biotechnology Ltd - qtrly ‍loss per share $0.02​.  Full Article

No consensus analysis data available.